Latest Generate:Biomedicines News & Updates

See the latest news and media coverage for Generate:Biomedicines. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Generate:Biomedicines

Generative biology drug discovery and development company

generatebiomedicines.com
Headquarters
Somerville, United States
Company type
Private company
Number of employees
300–500
Industry
Biotechnology & Medical Research

Last updated

Latest news about Generate:Biomedicines

In short: Generate:Biomedicines completed a $425 million IPO and advanced its AI-engineered asthma therapy, GB-0895, into global Phase 3 trials.

Company announcements

Generate:Biomedicines

Generate:Biomedicines reports Q1 2026 financial results

Pipeline advances include Phase 3 for GB-0895, first patient dosing for GB-4362 in mid-2026, and GB-5267 collaboration with Roswell Park. Cash and marketable securities totaled $516.6 million as of March 31.

Unlock all announcements with a

Media coverage

BioSpace

Behind the bell: Gearing up to go public

Avalyn Pharma and Generate Biomedicines executives discuss the long hours, hard work and rewarding moments of taking their companies public. For Lyn Baranowski, it all...

Yahoo Finance

Generate Biomedicines: Q2 Earnings Snapshot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage...

Unlock all articles with a

Never miss news about Generate:Biomedicines

Track Generate:Biomedicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Generate:Biomedicines competitors & trending companies

Browse news for competitors to Generate:Biomedicines and other trending companies.